WO2017118401A1 - 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒 - Google Patents
喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒 Download PDFInfo
- Publication number
- WO2017118401A1 WO2017118401A1 PCT/CN2017/070352 CN2017070352W WO2017118401A1 WO 2017118401 A1 WO2017118401 A1 WO 2017118401A1 CN 2017070352 W CN2017070352 W CN 2017070352W WO 2017118401 A1 WO2017118401 A1 WO 2017118401A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- esophageal cancer
- compound
- pharmaceutically acceptable
- administration
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Description
Claims (20)
- 权利要求1所述的方法,其中所述食管癌为食管鳞癌和/或食管腺癌。
- 权利要求1所述的方法,其中所述食管癌为晚期食管癌和/或转移性食管癌。
- 权利要求1所述的方法,其中所述食管癌为经紫杉烷类抗肿瘤药、长春碱类抗肿瘤药、铂配合物和/或嘧啶拮抗物治疗失败的食管癌;优选地,所述紫杉烷类抗肿瘤药选自紫杉醇和多西紫杉醇,所述长春碱类抗肿瘤药选自长春碱、长春新碱、长春地辛和长春瑞滨,所述铂配合物选自米铂、顺铂、卡铂、奈达铂和奥沙利铂,所述嘧啶拮抗物选自阿糖胞苷、安西他滨、卡培他滨、吉西他滨、氟尿嘧啶、双呋氟尿嘧啶、去氧氟尿苷、替加氟和卡莫氟。
- 根据权利要求1-4任一项所述的方法,其特征在于:化合物I的药学上可接受的盐为盐酸盐,优选二盐酸盐。
- 根据权利要求5所述的方法,其特征在于:化合物I或其药学上可接受的盐的给药日剂量为如下剂量中的一种:2毫克至20毫克、5毫克至20毫克、8毫克至20毫克、10毫克至16毫克、10毫克至14毫克、10毫克、12毫克、14毫克以及16毫克。
- 根据权利要求5所述的方法,其特征在于:以间隔给药的方法给予化合物I或其药学上可接受的盐,所述的间隔给药包括给药期和停药期,其中给药期和停药期以天数计的比值为2:0.5~5,优选2:0.5~3,较优选2:0.5~2,更优选2:0.5~1;作为优选的给药间隔给药方式,为如下方式中的一种:连续给药2周停药2周、连续给药2周停药1周以及连续给药5天停药2天,上述间隔给药方式可以反复进行多次。
- 根据权利要求8所述的用途,其中,其中所述食管癌为食管鳞癌和/或食管腺癌。
- 根据权利要求8所述的用途,其中所述食管癌为晚期食管癌和/或转移性食管癌。
- 根据权利要求8所述的用途,其中所述食管癌为经紫杉烷类抗肿瘤药、长春碱类抗肿瘤药、铂配合物和/或嘧啶拮抗物治疗失败的食管癌;优选地,所述紫杉烷类抗肿瘤药选自紫杉醇和多西紫杉醇,所述长春碱类抗肿瘤药选自长春碱、长春新碱、长春地辛和长春瑞滨,所述铂配合物选自米铂、顺铂、卡铂、奈达铂和奥沙利铂,所述嘧啶拮抗物选自阿糖胞苷、安西他滨、卡培他滨、吉西他滨、氟尿嘧啶、双呋氟尿嘧啶、去氧氟尿苷、替加氟和卡莫氟。
- 根据权利要求8-11任一项所述的用途,其中,化合物I的药学上可接受的盐为盐酸盐,优选二盐酸盐。
- 根据权利要求13所述的组合物,其中,所述食管癌为食管鳞癌和/或食管腺癌。
- 根据权利要求13所述的组合物,其中,所述食管癌为晚期食管癌和/或转移性食管癌。
- 根据权利要求13所述的组合物,其中,所述食管癌为经紫杉烷类抗肿瘤药、长春碱类抗肿瘤药、铂配合物和/或嘧啶拮抗物治疗失败的食管癌;优选地,所述紫杉烷类抗肿瘤药选自紫杉醇和多西紫杉醇,所述长春碱类抗肿瘤药选自长春碱、长春新碱、长春地辛和长春瑞滨,所述铂配合物选自米铂、顺铂、卡铂、奈达铂和奥沙利铂,所述嘧啶拮抗物选自阿糖胞苷、安西他 滨、卡培他滨、吉西他滨、氟尿嘧啶、双呋氟尿嘧啶、去氧氟尿苷、替加氟和卡莫氟。
- 根据权利要求13-16任一项所述的组合物,其中,化合物I的药学上可接受的盐为盐酸盐,优选二盐酸盐。
- 根据权利要求17所述的组合物,其特征在于:化合物I或其药学上可接受的盐的给药日剂量为如下给药日剂量中的一种:2毫克至20毫克、5毫克至20毫克、8毫克至20毫克、10毫克至16毫克、10毫克至14毫克、10毫克、12毫克、14毫克以及16毫克。
- 根据权利要求17所述的组合物,其特征在于:以间隔给药的方法给予化合物I或其药学上可接受的盐,所述的间隔给药包括给药期和停药期,其中给药期和停药期以天数计的比值为2:0.5~5,优选2:0.5~3,较优选2:0.5~2,更优选2:0.5~1;作为优选的给药间隔给药方式,为如下方式中的一种:连续给药2周停药2周、连续给药2周停药1周以及连续给药5天停药2天,上述间隔给药方式可以反复进行多次。
- 一种试剂盒,其包含(a)至少一个单位剂量的权利要求13-19中任一项所述的药物组合物和(b)用于治疗食管癌的说明书、尤其是以间隔给药的方式用于治疗食管癌的说明书;所述药物组合物优选为适于口服的制剂,更优选为片剂或胶囊。
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3010654A CA3010654A1 (en) | 2016-01-08 | 2017-01-06 | Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof |
JP2018535145A JP6855488B2 (ja) | 2016-01-08 | 2017-01-06 | 食道癌を治療するためのキノリン誘導体の使用とその治療方法、医薬組成物及びキット |
EP17735839.7A EP3400942B1 (en) | 2016-01-08 | 2017-01-06 | Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof |
CN202210812303.8A CN115025090A (zh) | 2016-01-08 | 2017-01-06 | 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒 |
AU2017205749A AU2017205749B2 (en) | 2016-01-08 | 2017-01-06 | Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof |
KR1020187022299A KR20180100614A (ko) | 2016-01-08 | 2017-01-06 | 식도암을 치료하기 위한 퀴놀린 유도체의 용도 및 치료방법, 이의 약제학적 조성물 및 키트 |
CN201780009721.0A CN108601778A (zh) | 2016-01-08 | 2017-01-06 | 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒 |
RU2018126829A RU2734260C2 (ru) | 2016-01-08 | 2017-01-06 | Применение производных хинолина для лечения рака пищевода, а также способ лечения, фармацевтическая композиция и набор с их использованием |
ES17735839T ES2913097T3 (es) | 2016-01-08 | 2017-01-06 | Uso de derivados de quinolina para el tratamiento del cáncer de esófago y método de tratamiento, composición farmacéutica y equipo de los mismos |
US16/068,332 US10561647B2 (en) | 2016-01-08 | 2017-01-06 | Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610013628 | 2016-01-08 | ||
CN201610013628.4 | 2016-01-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017118401A1 true WO2017118401A1 (zh) | 2017-07-13 |
Family
ID=59273281
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/070352 WO2017118401A1 (zh) | 2016-01-08 | 2017-01-06 | 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒 |
Country Status (10)
Country | Link |
---|---|
US (1) | US10561647B2 (zh) |
EP (1) | EP3400942B1 (zh) |
JP (1) | JP6855488B2 (zh) |
KR (1) | KR20180100614A (zh) |
CN (2) | CN108601778A (zh) |
AU (1) | AU2017205749B2 (zh) |
CA (1) | CA3010654A1 (zh) |
ES (1) | ES2913097T3 (zh) |
RU (1) | RU2734260C2 (zh) |
WO (1) | WO2017118401A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3766496A4 (en) * | 2018-03-14 | 2021-12-29 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline derivative for treatment of nasopharyngeal carcinoma |
US11419862B2 (en) | 2018-03-14 | 2022-08-23 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline derivative for treatment of nasopharyngeal carcinoma |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111643502A (zh) * | 2019-03-04 | 2020-09-11 | 正大天晴药业集团股份有限公司 | 喹啉衍生物联合化疗药物用于治疗非小细胞肺癌 |
GB2596271A (en) * | 2020-05-06 | 2021-12-29 | Nottingham Univ Hospitals Nhs Trust | Cancer screening test |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101809012A (zh) * | 2007-03-14 | 2010-08-18 | 南京爱德程医药科技有限公司 | 作为血管生成抑制剂的螺取代化合物 |
CN102344438A (zh) * | 2010-08-01 | 2012-02-08 | 江苏正大天晴药业股份有限公司 | 喹啉衍生物的结晶及其制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2186594C2 (ru) * | 2000-10-10 | 2002-08-10 | Российский онкологический научный центр им. Н.Н.Блохина РАМН | Способ лечения больных плоскоклеточным раком пищевода |
WO2008138184A1 (fr) * | 2007-05-14 | 2008-11-20 | Shanghai Hengrui Pharmaceutical Co.Ltd. | Dérivés de pyrrolo-azacycles, leur procédé de fabrication et leur utilisation en tant qu'inhibiteurs de protéine kinases |
BRPI0820564A2 (pt) * | 2007-11-13 | 2017-05-23 | Phoenix Biotechnology Inc | método para determinar a probabilidade de uma resposta terapêutica na quimioterapia do câncer com glicosídeo cardíaco |
CN105311029A (zh) * | 2014-06-06 | 2016-02-10 | 正大天晴药业集团股份有限公司 | 抗肿瘤活性的喹啉衍生物 |
CN105213394B (zh) * | 2014-06-06 | 2019-04-09 | 正大天晴药业集团股份有限公司 | 具有抗肿瘤活性的喹啉衍生物 |
-
2017
- 2017-01-06 CN CN201780009721.0A patent/CN108601778A/zh active Pending
- 2017-01-06 RU RU2018126829A patent/RU2734260C2/ru active
- 2017-01-06 ES ES17735839T patent/ES2913097T3/es active Active
- 2017-01-06 KR KR1020187022299A patent/KR20180100614A/ko not_active Application Discontinuation
- 2017-01-06 CA CA3010654A patent/CA3010654A1/en active Pending
- 2017-01-06 JP JP2018535145A patent/JP6855488B2/ja active Active
- 2017-01-06 US US16/068,332 patent/US10561647B2/en active Active
- 2017-01-06 EP EP17735839.7A patent/EP3400942B1/en active Active
- 2017-01-06 AU AU2017205749A patent/AU2017205749B2/en active Active
- 2017-01-06 CN CN202210812303.8A patent/CN115025090A/zh active Pending
- 2017-01-06 WO PCT/CN2017/070352 patent/WO2017118401A1/zh active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101809012A (zh) * | 2007-03-14 | 2010-08-18 | 南京爱德程医药科技有限公司 | 作为血管生成抑制剂的螺取代化合物 |
CN102344438A (zh) * | 2010-08-01 | 2012-02-08 | 江苏正大天晴药业股份有限公司 | 喹啉衍生物的结晶及其制备方法 |
Non-Patent Citations (2)
Title |
---|
See also references of EP3400942A4 * |
ZHU, LINYAN ET AL.: "mpact analysis of VEGF change and pathological reaction on prognosis of patients withesophageal cancer before and after radiation and chemotherapy", ANHUI MEDICAL AND PHARMACEUTICAL JOURNAL, vol. 19, no. 1, 31 January 2015 (2015-01-31), pages 70 - 73, XP009512033 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3766496A4 (en) * | 2018-03-14 | 2021-12-29 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline derivative for treatment of nasopharyngeal carcinoma |
US11419862B2 (en) | 2018-03-14 | 2022-08-23 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline derivative for treatment of nasopharyngeal carcinoma |
Also Published As
Publication number | Publication date |
---|---|
KR20180100614A (ko) | 2018-09-11 |
EP3400942B1 (en) | 2022-04-13 |
JP2019501185A (ja) | 2019-01-17 |
US10561647B2 (en) | 2020-02-18 |
AU2017205749B2 (en) | 2021-12-23 |
CA3010654A1 (en) | 2017-07-13 |
RU2018126829A3 (zh) | 2020-04-06 |
RU2734260C2 (ru) | 2020-10-13 |
RU2018126829A (ru) | 2020-01-20 |
JP6855488B2 (ja) | 2021-04-07 |
CN115025090A (zh) | 2022-09-09 |
EP3400942A1 (en) | 2018-11-14 |
AU2017205749A1 (en) | 2018-08-02 |
US20190022082A1 (en) | 2019-01-24 |
CN108601778A (zh) | 2018-09-28 |
EP3400942A4 (en) | 2019-10-16 |
ES2913097T3 (es) | 2022-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10888559B2 (en) | Quinoline derivatives for non-small cell lung cancer | |
CN109069500B (zh) | 一种用于治疗胃癌的喹啉衍生物 | |
WO2015185011A1 (zh) | 喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物 | |
WO2017118401A1 (zh) | 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒 | |
WO2018214925A1 (zh) | 用于治疗结直肠癌的喹啉衍生物 | |
WO2020057536A1 (zh) | 用于治疗脑肿瘤的喹啉衍生物 | |
CN111757736B (zh) | 治疗鼻咽癌的喹啉衍生物 | |
CN111757737B (zh) | 用于治疗三阴性乳腺癌的喹啉衍生物 | |
CN112533600B (zh) | 用于治疗小细胞肺癌的喹啉衍生物 | |
WO2016091167A1 (zh) | 抗肺鳞癌的喹啉衍生物 | |
WO2019223672A1 (zh) | 用于治疗非小细胞肺癌的喹啉衍生物 | |
EP3682883A1 (en) | Quinoline derivative for treatment of neuroendocrine tumors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17735839 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3010654 Country of ref document: CA Ref document number: 2018535145 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2018126829 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 20187022299 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020187022299 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2017205749 Country of ref document: AU Date of ref document: 20170106 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017735839 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017735839 Country of ref document: EP Effective date: 20180808 |